Kangstem Biotech Co. Ltd Asset Resilience Ratio
Kangstem Biotech Co. Ltd asset resilience ratio. Kangstem Biotech Co. Ltd (217730) has an Asset Resilience Ratio of 38.73% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Kangstem Biotech Co. Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Kangstem Biotech Co. Ltd (2016–2025)
Asset resilience ratio of Kangstem Biotech Co. Ltd from 2016 to 2025. This chart shows how Kangstem Biotech Co. Ltd's Asset Resilience Ratio has changed over time. Read Kangstem Biotech Co. Ltd (217730) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Kangstem Biotech Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Kangstem Biotech Co. Ltd's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩26.50 Billion | 38.73% |
| Total Liquid Assets | ₩26.50 Billion | 38.73% |
Asset Resilience Insights
- Very High Liquidity: Kangstem Biotech Co. Ltd maintains exceptional liquid asset reserves at 38.73% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Kangstem Biotech Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Kangstem Biotech Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Kangstem Biotech Co. Ltd Asset Resilience Ratio by Year (2016–2025)
Kangstem Biotech Co. Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Kangstem Biotech Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 44.91% | ₩36.60 Billion ≈ $24.80 Million |
₩81.49 Billion ≈ $55.23 Million |
+12.28pp |
| 2024-12-31 | 32.63% | ₩18.27 Billion ≈ $12.38 Million |
₩55.99 Billion ≈ $37.94 Million |
-13.35pp |
| 2023-12-31 | 45.98% | ₩37.36 Billion ≈ $25.32 Million |
₩81.25 Billion ≈ $55.06 Million |
+0.47pp |
| 2022-12-31 | 45.51% | ₩36.68 Billion ≈ $24.86 Million |
₩80.59 Billion ≈ $54.62 Million |
-9.33pp |
| 2021-12-31 | 54.84% | ₩56.57 Billion ≈ $38.34 Million |
₩103.15 Billion ≈ $69.90 Million |
+9.23pp |
| 2020-12-31 | 45.61% | ₩37.63 Billion ≈ $25.50 Million |
₩82.51 Billion ≈ $55.91 Million |
+32.88pp |
| 2019-12-31 | 12.73% | ₩14.47 Billion ≈ $9.81 Million |
₩113.64 Billion ≈ $77.01 Million |
-2.52pp |
| 2018-12-31 | 15.25% | ₩11.16 Billion ≈ $7.56 Million |
₩73.19 Billion ≈ $49.60 Million |
-8.51pp |
| 2017-12-31 | 23.76% | ₩10.91 Billion ≈ $7.39 Million |
₩45.91 Billion ≈ $31.12 Million |
-25.37pp |
| 2016-12-31 | 49.13% | ₩23.31 Billion ≈ $15.80 Million |
₩47.44 Billion ≈ $32.15 Million |
-- |
About Kangstem Biotech Co. Ltd
Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn's disease. It also provides stem cell conditioned media, such a… Read more